Topic: checkpoint inhibitors
In November, Merck said Keytruda had topped chemo at lengthening the lives of esophageal cancer patients. Monday, it showed the win was a big one.
Back in November, Pfizer and Merck KGaA reported that Bavencio had failed a late-stage ovarian cancer trial. And now they can make it two.
Merck’s latest Keytruda OK isn’t a huge one for the New Jersey pharma. But it’s a big deal for Bavencio drugmakers Pfizer and Merck KGaA.
When 2018 began, there was still plenty of uncertainty for I-O drugmakers in lung cancer. But as 2019 nears, Merck's dominance looks pretty clear.
AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.
BMS’s Opdivo failed a key small cell lung cancer trial in October, but the results may still be enough to protect the approval it already has.
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.
Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.
Bristol-Myers Squibb's PD-1 blocker Opdivo will be covered in Britain for the next two years—an important win for the embattled drug.